House ephedra hearings
This article was originally published in The Tan Sheet
Executive Summary
Energy & Commerce Committee ephedra investigation builds steam, with plans to hold two days of hearings in late July. Sports league heads, ephedra manufacturers, FDA reps likely will be called to testify. Committee chair Billy Tauzin (D-La.) and others send July 1 follow-up letter requesting FDA provide records on foreign ephedra investigations, AEs received since Sept. 30, 2001 close date of RAND report. Letter also requests records relating to FDA communications on the Boozer-Daly study often cited by ephedra proponents, and records relating to Hicksville, NY-based Phoenix Labs, which manufactured Xenadrine RFA-1 for Cytodyne. Investigation was launched in February with letters to McClellan, Cytodyne (1"The Tan Sheet" March 3, 2003, p. 9). Hearings for related inquiry into supplements marketed to children unlikely until after August recess...
You may also be interested in...
Ephedra Safety Taken Up By House Commerce Cmte, Cytodyne Sent Letter
The House Energy & Commerce Committee launched an investigation into the safety of ephedra Feb. 28 by sending letters to FDA Commissioner Mark McClellan, MD/PhD, and Cytodyne Technologies President Robert Chinery
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.